AllDocs -> cancers

Version 1.0 08/12/1999 June 20, 2003 EORTC Data Center Av. E. Mounier 83/11 1200 Brussels, Belgium Direct phone: + 32 2 774 16 11 Fax: + 32 2 772 35 45 EORTC GASTROINTESTINAL TRACT CANCER AND RADIOTHERAPY GROUP INTEREST FORM Randomised phase II/III study comparing Gemcitabine followed by Gemcitabine plus concomitant radiation (50.4 Gy) versus control after curative pancreaticoduodenectomy for pancreatic head cancer “40013/22012” I, the undersigned declare that I have read the proposed study outline and I am interested in entering patients in the study YES NO I understand that this procedure is not binding me/my center to the study but I realize that preliminary interest will be used to evaluate the potential accrual of the proposed trial and set up the study infrastructure Expected accrual per YEAR: ...

TNFerade TM Combined with Chemoradiation in Gastrointestinal Cancer : Phase I/II Studies in Unresectable Locally Advanced Pancreatic and Resectable Esophageal Cancer Neil Senzer, MD Scientific Director Mary Crowley Medical Research Center US Oncology, Dallas, TX On behalf of the TNFerade TM Investigators Page 2 What is TNFerade TM ? • TNFerade is a second-generation (E1-, partial E3-, and E4-deleted) adenovector carrying the transgene encoding for TNF- a • A radiation-inducible promoter (Egr-1) is incorporated in the construct to optimize spatial and temporal gene expression following ionizing radiation Page 3 Rationale of TNFerade and Radiation Therapy Transcriptional targeting using a radiation- inducible, radio-sensitizing ...

JOURNAL OF PATHOLOGY J. Pathol. 187 : 223–228 (1999) SYNTHESIS OF BASEMENT MEMBRANE BY GASTROINTESTINAL CANCER CELL LINES TAKUMI AKASHI 1 *, TIZUKO MIYAGI 1 , NOBORU ANDO 1 , YOSHIMI SUZUKI 1 , TETSUO NEMOTO 1 , YOSHINOBU EISHI 1 , KYOICHI NAKAMURA 1 , TAKUJI SHIRASAWA 2 , NATSUMI OSA 3 , NOBORU TANAKA 3 AND ROBERT E. BURGESON 4 1 Department of Pathology, Tokyo Medical and Dental University, Tokyo, Japan 2 Department of Molecular Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan 3 PCL Japan, Tokyo, Japan 4 Cutaneous Biology Center, Harvard Medical School, Charleston, MA, U.S.A. SUMMARY Gastrointestinal adenocarcinoma-derived ...

Novartis International AG Novartis Communications CH-4002 Basel Switzerland Tel + 41 61 324 2200 Fax + 41 61 324 3300 Internet address: http://www.novartis.com *In the US: Gleevec ® (imatinib mesylate) 1/2 MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG Glivec ® approved in Japan for treatment of life-threatening gastrointestinal cancer Basel, Switzerland, 17 July 2003 – Novartis announced today that health authorities in Japan have approved Glivec ® (imatinib)* for the treatment of patients with KIT (CD117) positive gastrointestinal stromal tumors (GISTs), a life-threatening cancer . Historically, GISTs have been very difficult to treat due to their resistance to treatment with available chemotherapy and radiation therapy. Previously, ...

B.C. Cancer Agency Protocol Summary GIFUC Page 1 of 3 H:\Pharm-prov\UPDATE\UpdateImplementation\GIFUC.doc PRINT DATE 2/5/2004 2:25 PM BCCA Protocol Summary for Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder Carcinoma and Cholangiocarcinoma) using Infusional Fluorouracil and Cisplatin Protocol Code: GIFUC Tumour Group: Gastrointestinal Contact Physician: GI Systemic Therapy ELIGIBILITY: Metastatic or unresectable adenocarcinoma of the upper gastrointestinal tract (stomach, esophagus, gall bladder, bile ducts) ECOG 0-2 EXCLUSIONS: CNS metastases Uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the preceding 6 months, serious uncontrolled cardiac dysrhythmia Inadequate ...

News Release: For immediate distribution ESMO and Imedex Announce Partnership for the World Congress on Gastrointestinal Cancer ® ALPHARETTA, Ga. 15 December 2004 – Imedex, Inc. and The European Society for Medical Oncology (ESMO) today announced their collaboration in the promotion of The World Congress on Gastrointestinal Cancer ® , a clinically-focused Congress that has attracted thousands of oncologists and gastroenterologists since its inception in 1999. In a joint statement Paris Kosmidis, MD and President of ESMO, Stefan Terwindt, President of the Congress organizer, Imedex, Inc., Eric Van Cutsem, MD, PhD, and Mario Dicato, MD, Congress co-chairmen, emphasized the benefits of collaboration and dedication to the future success of the Congress. "The World Congress on Gastrointestinal Cancer is the most important international meeting on ...

Connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria S. Suresh a,b, * , J. Spatz c , J.P. Mills a , A. Micoulet c , M. Dao a , C.T. Lim d , M. Beil e , T. Seufferlein e a Department of Materials Science and Engineering, and Division of Bioengineering, Massachusetts Institute of Technology, Room 8-309, 77 Massachusetts Ave., Cambridge, MA 02139-4307, USA b Division of Biological Engineering and Affiliated Faculty of the Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139-4307, USA c Institute for Physical Chemistry, Biophysical Chemistry, University of Heidelberg, INF 253, 69120Heidelberg, Germany d Division of Bioengineering and Department of ...

Centre for Clinical Research in Cancer Victorian Cooperative Oncology Group Key Published Articles Listing — Gastrointestinal Cancer (2000–2003) Title & Abstract Author Journal Is home screening for bowel cancer a good idea? (Editorial) Adelstein B, Trevena L, Barratt A & Salkeld G. Australian & New Zealand Journal of Public Health 2003; 27(3): 265–6. Multiple colorectal adenomas – Is their number up? (Editorial) Marra G & Jiricny J. The New England Journal of Medicine 27 Feb 2003; 348(9): 845–7. Multiple colorectal adenomas, classic adenomatous polyposis, and germ- line mutations in MYH Background: Germ-line mutations in the base-excision-repair gene MYH have been associated with recessive inheritance of multiple colorectal adenomas. Tumors from affected persons displayed excess somatic transversions of a guanine-cytosine ...

1 WORLD CONGRESS ON GASTROINTESTINAL CANCER Barcelona, June16-19, 2004 The world congress on gastrointestinal cancer has its origins in the regular meetings on pharmacological treatments of colorectal cancer , partly based on Eric Van Cutsem’s (Brussels) personal interest of this disease and his effort to establish an international forum for the discussion of developments and future strategies. The world congress is now also concerned with malignancies of the liver, bile ducts, pancreas and all of the esophagus-stomach-bowel. It attracts more than 2000 people, mostly from Europe, but also from all other parts of the world. Unlike most other annual congresses, there is no famous world association or federation behind the meeting, but rather a smaller group of dedicated oncologists backed by the pharmaceutical industry with an interest in oncology. The conference has no double sessions, ...

Abstract. Thymidine phosphorylase (TP) and dihydro- pyrimidine dehydrogenase (DPD) are considered to be key enzymes affecting the prognosis for patients with advanced gastrointestinal cancer . Preoperative examination of TP and DPD expression levels and assessment of these enzymes in inoperable cancer patients may contribute to successful treatment. We tried to prove the correlation of TP and DPD expression in preoperative specimens by endoscopy and in surgical specimens. The present study was designed to quantify TP and DPD levels by enzyme-linked immunosorbent assay (ELISA) in tumor tissue obtained from 30 gastrointestinal cancer patients by preoperative endoscopy and surgery, including 15 gastric and 15 colorectal cancers. Successful cases as those in which cancer cells were demonstrated histologically in preoperative specimens by endoscopy were 12 (success rate: 80%) in gastric ...

Long-acting Repeatable (Lar) Octreotide for Clinical Management of Gastrointestinal Cancer a report by Alessandra Mosca Managing Director, Department of Clinical Oncology, San Luigi Hospital, Orbassano, Italy on behalf of Novartis Pharma AG e-mail: ale.mos@libero.it Page 2 O C T R E O T I D E L A R I N G A S T R O I N T E S T I N A L T U M O U R S 2 Abstract Octreotide represents a novel approach to the treatment of various endocrinological and oncological disorders. Its effects are mediated through its interaction with the somatostatin receptor subtype 2, and to a lesser extent subtypes 5 and 3, and subsequent effects on hormone secretion. A long-acting repeatable (LAR) formulation of octreotide is now available. It is administered by intramuscular injection every 4 weeks. Results to date suggest that octreotide LAR appears ...

Page 1 GASTROINTESTINAL CANCER ANTIGEN (CA-199) ENZYME IMMUNOASSAY TEST KIT Catalog Number: GBE-1006 Intended Use Enzyme Immunoassay for the Quantitative Measurement of Gastrointestinal Cancer Antigen (CA -199) EIA in Human Serum Introduction A group of Sialosyl Lewis Antigen (SLA) defined as a mucin type of glycoprotein such as CA 19-9, CA 195, has come to be recognized as circulating cancer associated antigen for gastrointestinal cancer (GI tumor antigen). Malignancies of pancreas, stomach and colon express these markers in a significant number of such patients. The GI Tumor Antigen ELISA test will measure CA 19-9 like GI tumor antigen in sera. It provides an aid in the evaluation of symptomatic patients suspected of having pancreatic cancer or related diseases, and as an aid in monitoring pancreatic cancer ...

1 Questions for Gastrointestinal Drugs Advisory Committee Chemoprevention of Sporadic Colorectal Cancer (CRC) March 19, 2002 1) For individuals who are able and willing to undergo colonoscopic screening or surveillance, is either partial and/or complete suppression of colorectal adenomatous polyps a clinically meaningful benefit? Why or why not? If adenomatous polyp suppression is not a clinically meaningful benefit, what additional information would be needed to demonstrate that partial or complete suppression of polyps is of clinical benefit in such individuals? 2) A chemoprotective agent (CPA) that suppresses polyp growth may become resistant to drug effects. Additionally, it may preferentially allow small, invasive lesions to go undetected on colonoscopy while large, indolent lesions are identified and removed. If polyp suppression is used as an endpoint in clinical trials of a CPA: ...

Abstract: Significant benefits have been gained with pre or peri-operative nutritional support in surgical patients with malnutrition. Recent studies have also shown that some enteral formulas including certain nutrients like glutamine could provide more benefit than the standard formulas. In this prospective-randomized study, the effects of perioperative oral supplement with enteral formulas containing glutamine in comparison with a standard enteral formula in patients who were operated on for GI malignancies were examined. Thirty-two patients were divided into two groups: the study group was given oral supplement with an elemental diet (Alitraq ® ) for 7 days preoperatively and 10 days postoperatively as 30-35% of total daily requirement (standard hospital diet: 65- 70%), while the control group received a polymeric formula (Ensure ® ) as the ...